:

UKRAINE FOCUSES ON AI FOR CITIZENS, DIGITAL RESILIENCE

AI DESK1 MIN READ
FRI, JUN 19, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

Ukraine's Deputy Minister of Digital Transformation Nataliia Denikeieva outlined the country's strategy for artificial intelligence development and digital resilience at VivaTech in Paris.

Denikeieva addressed Bloomberg's Francine Lacqua and Tom Mackenzie at the VivaTech x Bloomberg Awards, emphasizing Ukraine's commitment to building AI systems that serve its citizens. The discussion centered on digital resilience as a priority for Ukraine, particularly given the ongoing security challenges facing the nation. Denikeieva's remarks highlighted the government's focus on leveraging artificial intelligence to strengthen digital infrastructure and public services. Ukraine's digital transformation ministry has increasingly prioritized AI development as part of broader efforts to modernize government operations and citizen services. The country has positioned itself as a tech innovation hub despite geopolitical pressures. Denikeieva's appearance at the Paris event underscored Ukraine's engagement with international tech leaders and continued investment in digital capabilities.

■ SOURCES

Bloomberg Tech

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE AI DESK

Stanford and Arc Institute researchers used artificial intelligence to design complete viral genomes that successfully eliminated bacteria in laboratory tests. The team describes the work as the first generative design of complete genomes.

JUST NOWAI Desk

The Trump administration has finalized a framework for testing AI models on safety and cybersecurity risks, but is keeping the details confidential. The decision limits public transparency while potentially benefiting companies seeking less scrutiny.

JUST NOWAI Desk

ByteDance is developing an AI model with up to 10 trillion parameters, making it three times larger than Moonshot's Kimi K3, currently China's biggest model.

JUST NOWAI Desk

Roche is partnering with Recursion, an AI drug discovery company, to identify new targets for brain diseases. The collaboration aims to accelerate drug development and reduce costly failed trials.

1H AGOAI Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.